• AdAlta forms a clinical advisory board to advance its lead i-body enabled drug candidate AD-214
• Board members are renowned experts in pulmonary medicine and fibrosis
• AdAlta has also engaged a specialist adviser for Idiopathic Pulmonary Fibrosis translational science

Special Report: Clinical stage biotech AdAlta has formed a clinical advisory board (CAB) and appointed an additional adviser to advance its lead asset AD-214, which is being developed to treat Idiopathic Pulmonary Fibrosis (IPF).

AdAlta (ASX:1AD) said the strategic appointments were part of the company’s ongoing preparations for upcoming Phase 2 clinical trials of its lead i-body enabled drug candidate AD-214.

Pending completion of financing arrangements, the Phase 2 trial is expected to build on the positive results observed in Phase 1 studies.

The newly created CAB marks another milestone in AdAlta’s broader strategy to advance the development and commercialisation of AD-214.

1AD said the first-in-class molecule was showing promise to improve outcomes for more than 500k patients worldwide with IPF, a disease for which there is no cure.

Pulmonary medicine and fibrosis experts

The newly created CAB is comprised of internationally recognised experts in pulmonary medicine and fibrosis, each bringing a wealth of experience from multiple IPF clinical trials.

Members include:

Professor Tamera Corte: Affiliated with both the Royal Prince Alfred Hospital in Sydney and the University of Sydney, Corte is the chief investigator on the Centre of Research Excellence for Pulmonary Fibrosis and chair of the steering committee for the Australian Idiopathic Pulmonary Fibrosis Registry. She has extensive experience in IPF research and clinical trials.

Professor Toby Maher: A respiratory physician and researcher at the Keck School of Medicine, University of Southern California, Maher has been the global chief investigator for multiple IPF trials and has recruited more than 1,000 subjects for 35+ clinical studies.

Professor Marlies Wijsenbeek-Lourens: Based at Erasmus University Rotterdam, she is a leading pulmonologist specialising in IPF and other interstitial lung diseases (ILD), chairing the Erasmus MC multidisciplinary ILD centre.

Professor Philip Molyneaux: Lead consultant for clinical trials in pulmonary fibrosis at Royal Brompton and Harefield Hospitals and director of the NIHR cardiorespiratory clinical research facility, his research has advanced therapeutic approaches for IPF.

Dr Steve Felstead MB ChB: Transitioning from 1AD’s scientific advisory board to the CAB Felstead brings extensive clinical drug development expertise and was formerly vice president and head of clinical research at Pfizer. He is currently CMO at Juvenescence Ltd.

Translational science adviser joins team

1AD has also appointed Professor Gisli Jenkins from Imperial College London as a specialist adviser for translational science.

He leads the Margaret Turner Warwick Centre for Fibrosing Lung Diseases at the National Heart and Lung Institute and is an honorary consultant physician at Royal Brompton Hospital.

AdAlta said Jenkins’ expertise in bridging laboratory research and clinical application will be invaluable as AdSolis advances AD-214.

‘Significant step forward’

1AD CEO and managing director Tim Oldham said the formation of the CAB, alongside the appointment of a translational science adviser, underscores the company’s commitment to advancing AD-214 to its next development stage.

He said the collective expertise and global reach of these healthcare professionals would be crucial in guiding AD-214’s Phase 2 clinical trial preparations and ensuring its success.

“Our efforts to develop AD-214 have taken a significant step forward with the creation of our Clinical Advisory Board and the appointment of a specialist adviser for translational science,” he said.

“These highly skilled professionals are not only experts in treating Idiopathic Pulmonary Fibrosis, but they also bring immense experience in delivering IPF clinical trials. We welcome them to AdAlta as we advance the development of AD-214.”

This article was developed in collaboration with AdAlta, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.